Replies to post #333030 on Innovation Pharmaceuticals Inc (IPIX)

[cybermich]

lol.. so you will retract your statement (post?)

It kind of nullifies the basis for your attack on the company and its CEO..

In fact it is mind boggling how you could make such statements and at the same time

not even be aware of the basic fundamentals of this company.

[MinnieM]

For those that aren't aware, keep in mind during research that Brilacidin and PMX-30063 are the same drug. Some issues that were present in PMX-30063 ph2 ABSSSI trial were solved in Brilacidin ph2b ABSSSI trial via lower dosing.

PMX-30063 was tested in clinical trials by PolyMedix.
Brilacidin was tested in clinical trials by Cellceutix that is now Innovation Pharmaceuticals.

ABSSSI trials are the only ones to have been done via IV dosing which is expected to be done in the upcoming Brilacidin covid trial. Other indications in clinical trials with Brilacidin were using various other means of dosing. Swish & spit (OM), enema (UP), and oral tablet (UC)

Aerosol and Intramuscular are untested dosing means for Brilacidin at this point in time.

An officially unnamed company has tested Brilacidin for biofilm use. Many believe it is a part of J&J.

Following are some related bits of data, not all, but, I only had time to grab this without doing a full search:


Population Pharmacokinetic Analyses of Brilacidin Using Data from Healthy Subjects and Patients with Acute Bacterial Skin and Skin Structure Infections

23rd Poster No. P 917 European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany. April 27-30, 2013

https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f849d1b631be3d85bd2a5/1480557726468/B00292_brilacidin_ppk_ECCMID13_19apr13-1.pdf

*****

AAC Accepts, published online ahead of print on 16 June 2014
Antimicrob. Agents Chemother. doi:10.1128/AAC.02955-14
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

https://aac.asm.org/content/aac/early/2014/06/11/AAC.02955-14.full.pdf

*****
ECCMID 2015 Copenhagen, Denmark 25 – 28 April 2015
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f8286d2b85731b8713a36/1480557192947/A-Randomized-Double-Blind-Study-Comparing-Single-Dose-and-Short-Course-Brilacidin-to-Daptomycin-in-the-Treatment-of-Acute-Bacterial-Skin-Skin-Structure-Infections-ABSSSI1.pdf

*****

Application of Pharmacokinetic-Pharmacodynamic Models for Brilacidin Dose Selection Support for Patients with Acute Bacterial Skin and Skin Structure Infections

American Society for Microbiology Microbe 2016, Boston, MA. June 16-20, 2016
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f831e579fb3daf479520c/1480557343791/Application-of-Pharmacokinetic-Pharmacodynamic-Models-for-Brilacidin-Dose-Selection-Support-for-Patients-with-Acute-Bacterial-Skin-and-Skin-Structure-Infections-.pdf

*****





Message in reply to: sunspotter

Thanks- that’s helpful.